Dec 12, 2016 by Brian FeroldiWhy Alexion Pharmaceuticals, Inc.'s Shareholders Lost $3 Billion TodayShares plunged after the company announced a surprise change to its senior management team.
Dec 12, 2016 by Brian Feroldi2 Companies I Wish I'd Bought in 2016This Motley Fool contributor regrets not pulling the trigger on these companies when he had the chance.
Dec 12, 2016 by Brian Feroldi3 Changes to Medicare in 2017Premiums and deductibles are heading higher in 2017. Here are the details you need to know.
Dec 11, 2016 by Brian FeroldiMy Biggest Investing Regret of 2016I should have bought shares of this biotech winner when I had the chance.
Dec 9, 2016 by Brian FeroldiDuluth Holdings Inc.'s Q3 Results Come Up ShortThe niche apparel retailer cuts full-year guidance.
Dec 9, 2016 by Brian FeroldiWhy Duluth Holdings Inc Stock Is Plunging TodayShares dropped in response to disappointing third-quarter results and a cut to full-year guidance.
Dec 9, 2016 by Brian FeroldiIs Celgene a Buffett Stock?How does the biotech giant stack up against Buffett's acquisition criteria?
Dec 6, 2016 by Brian FeroldiWhy TherapeuticsMD Inc. Jumped TodayShares pop in response to the company reporting encouraging results from an important late-stage clinical trial.
Dec 6, 2016 by Brian FeroldiHere's Why Organovo Holdings Inc. Vaulted 11% in NovemberTriple-digit sales growth mixed with a bullish long-term outlook send shares up by double digits.
Dec 6, 2016 by Brian FeroldiThis Is Why Keryx Biopharmaceuticals Surged 28% in NovemberA string of positive developments caused shares to rally.
Dec 6, 2016 by Brian FeroldiBetter Buy: MannKind Corp. vs. Novo NordiskWhich of these diabetes-focused companies is the better bet for new money today?
Dec 5, 2016 by Brian FeroldiHere's Why Regeneron Pharmaceuticals, Inc. Jumped 9.4% in NovemberShares rallied in response to the general uptick in the biotech sector and a string of positive announcements.
Dec 5, 2016 by Brian FeroldiIs This Why Sarepta Therapeutics Fell 14.5% in November?Shares of the rare-disease-focused drugmaker fell by double digits on little news. Was the decline caused by building skepticism regarding Sarepta's ability to get broad insurance coverage for Exondys 51?
Dec 5, 2016 by Brian FeroldiHere's Why ACADIA Pharmaceuticals Jumped 17.7% in NovemberShares rallied hard in response to a number of positive announcements.
Dec 5, 2016 by Brian Feroldi, Matt DiLallo, and Timothy Green3 Stocks We're Never SellingLooking for a few great company to buy and hold for the ultra long term? Our team of Fools thinks these three stocks are worth a closer look.
Dec 4, 2016 by Brian Feroldi7 of the Most Shocking Biotech Pipeline Blowups of 2016Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.
Dec 4, 2016 by Brian FeroldiDoes Pfizer Pass Warren Buffett’s Test?How does the pharma giant stack up against Buffett's acquisition criteria?
Dec 4, 2016 by Brian Feroldi5 Facts About Medicare Every Baby Boomer Should KnowWill you be turning 65 in the not-too-distant future? Make sure you know these essential Medicare facts before you apply for benefits.
Dec 3, 2016 by Brian FeroldiWhy Array BioPharma Rose 32.5% in NovemberManagement succeeded at building up investors' excitement about the company's future at two healthcare conferences during the month, which caused shares to rally.
Dec 3, 2016 by Brian FeroldiWhy Eli Lilly Shares Lost 8% in NovemberThe stock cratered after the drugmaker reported bummer news from an important late-stage clinical trial.
